Sex: M
Vaccine: DTAP, HEP, HIBV, IPV, HEP
Symptoms: Regressive behaviour, Repetitive speech, Sleep apnoea syndrome, Social avoidant behaviour, Speech disorder
Clinical narrative: Information has been received from a legal firm regarding a case in litigation concerning an approximately 12-month-old male born preterm at 35 weeks, who's mother had a subchorionic hemorrhage in utero at 6 weeks gestation, who was injected with vaccines reportedly containing Thimerosal. It is alleged that between 12 and 25 micrograms of toxic ethylmercury were injected into the patient's body with each individual dose of Thimerosal and that the schedule of injections introduced a cumulative dose of 238 micrograms. It is further alleged that on approximately 01-JUN-2000, at approximately 12 months of age, the patient began to display symptoms of neurological damage consistent with mercury poisoning, not limited to losing his language skills, engaging in repetitive and stereotypical behaviors, suffering from diminished cognitive ability and becoming socially withdrawn. At approximately 18 months of age, the patient suddenly regressed developmentally. He became withdrawn, unable to speak and unresponsive to his environment. His injuries included a loss of language skills, motor skills, and effect. The patient has since been diagnosed as suffering with mercury poisoning and disintegrative (or late onset, degenerative or regressive) autism.  Follow up information was received from a legal firm that indicated that the patient was exposed to airborne vapors and mercury through the food chain, other mercury-laden products and power plant emissions. The patient was exposed to mercury from continually inhaling and ingesting industrial mercury emissions from fossil fuel driven power plants. The mercury included in the thimerosal-laden products and power plant emissions together caused him to suffer serious and permanent injuries, including mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments. The patient had heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. Follow-up information received from medical records on 28-MAR-2007 indicated that a male patient with no reported allergies was vaccinated with a first,second and third IM dose of hepatitis B vaccine on 23-MAY-1999, 23-JUN-1999 (lot # 629637/1944H) and 21-FEB-2000 (lot # 634529/1947J). Secondary suspect vaccination included a first SC dose of MMR II (lot # 630638/0104K) on 24-MAY-2000. Additional vaccination on 24-MAY-2000 included a first SC dose of Varivax (lot # 632718/1856J). Additional vaccination history included a first, second, third, and fourth IM dose of Dtap on 21-FEB-1999 (lot # 462-312), 22-SEP-1999 (lot # 456-818), 22-NOV-1999 (lot # 456-818), 25-OCT-2000; a first IM dose of Hib vaccine (unspecified carrier) on 21-JUL-1999 (lot # 460103A); a first and second IM dose of Hib conj vaccine (tet toxoid) on 22-SEP-1999 (lot # N1045AA) and 22-NOV-1999 (lot # 1045AA); a first and second oral dose of poliovirus vaccine on 21-JUL-1999 (lot # P1212) and 22-SEP-1999 (lot # P0257). Follow-up information received on 28-MAR-2007 contained the following adverse events: congested (24-AUG-1999), vomiting (24-AUG-1999), coughing (24-AUG-1999 and 09-MAR-2000), gastroesophageal reflux (MARCH 2000), not eating, only drinking from bottle (29-NOV-2000), reactive airway disease/asthma (2001), large adenoids (hospitalization and surgery 17-AUG-2001), sleep-disorder breathing (2001). Upon internal review, autism, mercury poisoning, neurological injuries, permanent injuries (included mental, intellectual, developmental), learning disability, learning disorder, and neurological disorder were considered to be other important medical events. No further information is available.